PALI PALISADE BIO INC

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at being held October 25-30, 2024 in Philadelphia, PA.

The American College of Gastroenterology (ACG) is a recognized leader in educating GI professionals and the general public about digestive disorders. For more information about the ACG Annual Meeting, please visit the .

About Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
15/10/2024

Underlying

PALIPALISADE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALISADE BIO INC

 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Versto...

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon...

February 17, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets...

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that , will participate in a virtual fireside chat at the Piper Sandler Virtual N...

February 9, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life...

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that , will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in ...

February 5, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Birou...

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn’s disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisad...

January 29, 2026 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Two Abstracts Selected for Poster Presentations...

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead pr...

January 16, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch